Eisai sues FDA for more patent life

Share this article:

Tokyo-based drugmaker Eisai says the FDA owes it some extra patent time on weight-loss treatment Belviq and on epilepsy treatment Fycompa. Both drugs are classified by the Drug Enforcement Agency as controlled substances. While both were approved by the FDA, Eisai was unable to market either product until they were properly scheduled. Eisai claims it's entitled to one year of extra time on Belviq's patent and seven months on Fycompa's. The drugmaker made the claims in a lawsuit filed against the FDA in a bid to extend their market exclusivity.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters